Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis

To report the first patient with ocular toxoplasmosis treated with a slow-release biodegradable intravitreal clindamycin implant. A 39-year-old human immunodeficiency virus (HIV)-positive woman with recurrent toxoplasmic retinochoroiditis and vitritis for whom oral medication was medically contraind...

Full description

Saved in:
Bibliographic Details
Published in:American journal of ophthalmology case reports 2021-06, Vol.22, p.101093, Article 101093
Main Authors: Jorge, Rodrigo, Coelho, Igor Neves, Silva-Cunha, Armando, Fernandes Cunha, Gabriella Maria, Scott, Ingrid U., Fialho, Silvia Ligório, Furtado, João Marcello
Format: Article
Language:English
Subjects:
Case Report
Clindamycin
Implant
Intravitreal
Toxoplasmosis
Uveitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To report the first patient with ocular toxoplasmosis treated with a slow-release biodegradable intravitreal clindamycin implant. A 39-year-old human immunodeficiency virus (HIV)-positive woman with recurrent toxoplasmic retinochoroiditis and vitritis for whom oral medication was medically contraindicated was treated with an intravitreal slow-release clindamycin implant and three monthly intravitreal injections of clindamycin and dexamethasone. Serial ophthalmologic examinations demonstrated gradual, complete resolution of posterior uveitis and healing of the retinochoroidal lesion with cicatricial changes, as well as gradual improvement of cells in the anterior chamber. There was no significant change in electroretinography waves after treatment with the implant. The presence of the implant, or part of it, was detectable in the vitreous cavity for 4 months. To date, the patient has been monitored for 30 months, and there has been no reactivation of ocular toxoplasmosis. The slow-release clindamycin implant was safe for intravitreal use in this patient and may have contributed to the long-term control of toxoplasmosis chorioretinitis.
ISSN:2451-9936
2451-9936
DOI:10.1016/j.ajoc.2021.101093